| Rick Balestra, MD | |
|
1111 Ne 99th Ave Ste 200, Portland, OR 97220-9442 | |
| (503) 963-3030 | |
| (503) 963-3140 |
| Full Name | Rick Balestra |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 21 Years |
| Location | 1111 Ne 99th Ave Ste 200, Portland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184824351 | NPI | - | NPPES |
| 2078063 | Medicaid | WA | |
| 500679518 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD169371 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Portland Medical Center | Portland, OR | Hospital |
| Legacy Mount Hood Medical Center | Gresham, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Clinic Pc | 2860390408 | 319 |
News Archive
The George Washington University (GW) School of Medicine and Health Sciences is pleased to announce the establishment of a new, online Integrative Medicine Program, in partnership with the Metabolic Medical Institute.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
Emergencies at educational establishments are on the increase in recent years and campus officials are beginning to recognize that better communications with their students are now needed. Writing in the International Journal of Business Information Systems, US researchers describe how social networking sites might be exploited when an emergency situation arises to help safeguard students as well as keeping those not directly involved in the situation informed of events. The same insights might be applied in the business environment too.
A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.
› Verified 3 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003991845 PECOS PAC ID: 5395656284 Enrollment ID: O20031113000626 |
News Archive
The George Washington University (GW) School of Medicine and Health Sciences is pleased to announce the establishment of a new, online Integrative Medicine Program, in partnership with the Metabolic Medical Institute.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
Emergencies at educational establishments are on the increase in recent years and campus officials are beginning to recognize that better communications with their students are now needed. Writing in the International Journal of Business Information Systems, US researchers describe how social networking sites might be exploited when an emergency situation arises to help safeguard students as well as keeping those not directly involved in the situation informed of events. The same insights might be applied in the business environment too.
A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.
› Verified 3 days ago
| Entity Name | Oregon Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265417174 PECOS PAC ID: 2860390408 Enrollment ID: O20031222000096 |
News Archive
The George Washington University (GW) School of Medicine and Health Sciences is pleased to announce the establishment of a new, online Integrative Medicine Program, in partnership with the Metabolic Medical Institute.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
Emergencies at educational establishments are on the increase in recent years and campus officials are beginning to recognize that better communications with their students are now needed. Writing in the International Journal of Business Information Systems, US researchers describe how social networking sites might be exploited when an emergency situation arises to help safeguard students as well as keeping those not directly involved in the situation informed of events. The same insights might be applied in the business environment too.
A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.
› Verified 3 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366536963 PECOS PAC ID: 6103728753 Enrollment ID: O20040123000371 |
News Archive
The George Washington University (GW) School of Medicine and Health Sciences is pleased to announce the establishment of a new, online Integrative Medicine Program, in partnership with the Metabolic Medical Institute.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
Emergencies at educational establishments are on the increase in recent years and campus officials are beginning to recognize that better communications with their students are now needed. Writing in the International Journal of Business Information Systems, US researchers describe how social networking sites might be exploited when an emergency situation arises to help safeguard students as well as keeping those not directly involved in the situation informed of events. The same insights might be applied in the business environment too.
A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.
› Verified 3 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053862714 PECOS PAC ID: 7315856010 Enrollment ID: O20040304001330 |
News Archive
The George Washington University (GW) School of Medicine and Health Sciences is pleased to announce the establishment of a new, online Integrative Medicine Program, in partnership with the Metabolic Medical Institute.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
Emergencies at educational establishments are on the increase in recent years and campus officials are beginning to recognize that better communications with their students are now needed. Writing in the International Journal of Business Information Systems, US researchers describe how social networking sites might be exploited when an emergency situation arises to help safeguard students as well as keeping those not directly involved in the situation informed of events. The same insights might be applied in the business environment too.
A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.
› Verified 3 days ago
| Entity Name | Providence Health & Services - Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912282369 PECOS PAC ID: 5294901922 Enrollment ID: O20120319000430 |
News Archive
The George Washington University (GW) School of Medicine and Health Sciences is pleased to announce the establishment of a new, online Integrative Medicine Program, in partnership with the Metabolic Medical Institute.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
Emergencies at educational establishments are on the increase in recent years and campus officials are beginning to recognize that better communications with their students are now needed. Writing in the International Journal of Business Information Systems, US researchers describe how social networking sites might be exploited when an emergency situation arises to help safeguard students as well as keeping those not directly involved in the situation informed of events. The same insights might be applied in the business environment too.
A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rick Balestra, MD 847 Ne 19th Ave Ste 300, Portland, OR 97232-2686 Ph: (503) 963-2801 | Rick Balestra, MD 1111 Ne 99th Ave Ste 200, Portland, OR 97220-9442 Ph: (503) 963-3030 |
News Archive
The George Washington University (GW) School of Medicine and Health Sciences is pleased to announce the establishment of a new, online Integrative Medicine Program, in partnership with the Metabolic Medical Institute.
DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.
Emergencies at educational establishments are on the increase in recent years and campus officials are beginning to recognize that better communications with their students are now needed. Writing in the International Journal of Business Information Systems, US researchers describe how social networking sites might be exploited when an emergency situation arises to help safeguard students as well as keeping those not directly involved in the situation informed of events. The same insights might be applied in the business environment too.
A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.
› Verified 3 days ago
Salona Shrestha, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |